Bhoir S, De Benedetti A
Cancers (Basel). 2025; 17(1.
PMID: 39796704
PMC: 11718964.
DOI: 10.3390/cancers17010075.
Tyagi S, Tyagi S
Indian J Endocrinol Metab. 2024; 27(6):476-479.
PMID: 38371191
PMC: 10871014.
DOI: 10.4103/ijem.ijem_53_23.
Isaacs J
Am J Clin Exp Urol. 2023; 11(3):194-205.
PMID: 37441442
PMC: 10333130.
Megerian M, Kim J, Badreddine J, Hong S, Ponsky L, Shin J
Aging Dis. 2023; 14(3):840-857.
PMID: 37191417
PMC: 10187692.
DOI: 10.14336/AD.2022.1010.
Wan L, Thomas-Ahner J, Pearl D, Erdman Jr J, Moran N, Clinton S
J Nutr. 2023; 153(7):1877-1888.
PMID: 37187350
PMC: 10375503.
DOI: 10.1016/j.tjnut.2023.05.015.
Mipsagargin: The Beginning-Not the End-of Thapsigargin Prodrug-Based Cancer Therapeutics.
Isaacs J, Brennen W, Christensen S, Denmeade S
Molecules. 2021; 26(24).
PMID: 34946547
PMC: 8707208.
DOI: 10.3390/molecules26247469.
Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
Brennen W, Zhu Y, Coleman I, Dalrymple S, Antony L, Patel R
JCI Insight. 2021; 6(8).
PMID: 33724955
PMC: 8119192.
DOI: 10.1172/jci.insight.146827.
A Multifunctional LNA Oligonucleotide-Based Strategy Blocks AR Expression and Transactivation Activity in PCa Cells.
Castanotto D, Zhang X, Ruger J, Alluin J, Sharma R, Pirrotte P
Mol Ther Nucleic Acids. 2020; 23:63-75.
PMID: 33335793
PMC: 7723773.
DOI: 10.1016/j.omtn.2020.10.032.
Covid-19 pathogenesis in prostatic cancer and TMPRSS2-ERG regulatory genetic pathway.
Afshari A, Janfeshan S, Yaghobi R, Roozbeh J, Azarpira N
Infect Genet Evol. 2020; 88:104669.
PMID: 33301988
PMC: 7720011.
DOI: 10.1016/j.meegid.2020.104669.
Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
Zhu Y, Dalrymple S, Coleman I, Zheng S, Xu J, Hooper J
Oncogene. 2020; 39(45):6935-6949.
PMID: 32989253
PMC: 7655549.
DOI: 10.1038/s41388-020-01479-6.
Testosterone and prostate health: Have the paradigms truly shifted?.
Morales A, Siemens D
Can Urol Assoc J. 2020; 14(8):230-234.
PMID: 32931422
PMC: 7402689.
DOI: 10.5489/cuaj.6549.
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Hamid A, Petreaca R
Cancers (Basel). 2020; 12(4).
PMID: 32283832
PMC: 7226513.
DOI: 10.3390/cancers12040927.
Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC).
Isaacs J, Brennen W, Denmeade S
Ann Transl Med. 2020; 7(Suppl 8):S311.
PMID: 32016030
PMC: 6976443.
DOI: 10.21037/atm.2019.10.32.
Factors that influence the androgen receptor cistrome in benign and malignant prostate cells.
Copeland B, Du J, Pal S, Jones J
Mol Oncol. 2019; 13(12):2616-2632.
PMID: 31520575
PMC: 6887583.
DOI: 10.1002/1878-0261.12572.
Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.
Testa U, Castelli G, Pelosi E
Medicines (Basel). 2019; 6(3).
PMID: 31366128
PMC: 6789661.
DOI: 10.3390/medicines6030082.
BTF3 sustains cancer stem-like phenotype of prostate cancer via stabilization of BMI1.
Hu J, Sun F, Chen W, Zhang J, Zhang T, Qi M
J Exp Clin Cancer Res. 2019; 38(1):227.
PMID: 31138311
PMC: 6540453.
DOI: 10.1186/s13046-019-1222-z.
CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.
Augello M, Liu D, Deonarine L, Robinson B, Huang D, Stelloo S
Cancer Cell. 2019; 35(4):603-617.e8.
PMID: 30930119
PMC: 6467783.
DOI: 10.1016/j.ccell.2019.03.001.
Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer.
Akinboye E, Brennen W, Denmeade S, Isaacs J
Asian J Urol. 2019; 6(1):99-108.
PMID: 30775253
PMC: 6363604.
DOI: 10.1016/j.ajur.2018.11.004.
Mesenchymal stem cells and the embryonic reawakening theory of BPH.
Brennen W, Isaacs J
Nat Rev Urol. 2018; 15(11):703-715.
PMID: 30214054
PMC: 7050678.
DOI: 10.1038/s41585-018-0087-9.
Resolving the Coffey Paradox: what does the androgen receptor do in normal vs. malignant prostate epithelial cells?.
Isaacs J
Am J Clin Exp Urol. 2018; 6(2):55-61.
PMID: 29666833
PMC: 5902723.
